Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Nocturnal pain and gastric hypersecretion are common in duodenal ulcer. Therefore, we investigated the antisecretory effects of a new H2-receptor antagonist, cimetidine, in 200-, 300- or 400-mg doses, taken orally at bedtime. The 200-mg dose did not cause a statistically significant change in nocturnal (midnight to 7 a.m.) acid output and had only a borderline effect on pH. However, the 300-mg and 400-mg doses significantly (P less than 0.001) lowered acid output and increased (P less than 0.01) intragastric pH. All doses caused substantial decreases in secretory volume output. After a 400-mg dose, half the patients remained anacidic for eight hours. Dose-related increases of drug blood levels were observed and correlated with the degree and duration of inhibition of acid output. Serum gastrin levels were unaffected. Cimetidine appears to be a potent inhibitor of nocturnal gastric secretion.
 ...
PMID:Cimetidine suppression of nocturnal gastric secretion in active duodenal ulcer. 0 70

Eight patients with a clinical, radiology and endoscopic diagnosis of benign peptic ulcer were studied in a prospective fashion using Cimetidine (H2-Receptor antagonist). With this outgoing form of therapy the need for antiacid diminished greatly and pain totally disappeared. We discuss the possible etiological pathways of gastric ulcer and finally propose the simultaneous use of H2-Receptor antagonist and colesteramine with the goal of eliminating the two predominant factors that cause the lesion.
 ...
PMID:[Histamine 2 receptor antagonists in the treatment of gastric ulcer]. 1 9

Twenty-seven patients with symptomatic gastro-oesophageal reflux received cimetidine 1.6 g daily for 6 weeks and matching placebo for 6 weeks in a randomised double-blind crossover trial. They complained of significantly more episodes of pain on placebo than on cimetidine (1186 vs 581) and consumed significantly more antacid tablets on placebo than on cimetidine (1645 vs. 1011). Cimetidine and placebo had similar effects on mucosal sensitivity to acid and on oesophagitis assessed endoscopically and histologically, suggesting that the symptomatic benefit is the result of a simple antacid effect.
 ...
PMID:Effect of cimetidine in symptomatic gastro-oesophageal reflux. 8 86

The child's gastroduodenal ulcer is not uncommon. Its symptomatology is notably different from the adult's and gives it a rather original aspect. The pain is often atypical, almost permanent and its rythm is not necessarily related to the meals. The psychological context and the family background are almost always disclosed. The digestive hemorrhage is easily revealing. Radiological traps are to be known. The treatment is virtually always medical. Cimetidine has been used only in complications, in which it has appeared very useful. Surgery is not called for but in case of perforation or hemorrhage; then it is essentially preserving.
 ...
PMID:[The child's gastroduodenal ulcer (author's transl)]. 21 94

Forty-five adult outpatients with endoscopically confirmed gastric ulceration completed a double-blind trial of either cimetidine (1 g/day) or placebo. After six weeks 18 of the 23 patients receiving cimetidine showed complete ulcer healing compared with only six of the 22 patients receiving placebo. The cimetidine group also had fewer days with pain than the placebo group but the difference was not statistically significant. Cimetidine therefore seems to promote healing of gastric ulcers without severe side effects, although its effect on pain is less pronounced than in patients with duodenal ulcers.
 ...
PMID:Cimetidine in patients with gastric ulcer: a multicentre controlled trial. 33 36

A total of 55 patients were treated with the histamine H2-receptor antagonist cimetidine (Tagamet: SKF) in an endoscopically controlled double-blind trial. Cimetide (200 or 300 mg every 6 hours) was administered to 36 patients, and placebo to 19 patients. Only patients who had been confirmed by endoscopy as having uncomplicated duodenal ulcers were admitted to the trial. Drug or placebo was administered in a randomized double-blind fashion for 6 weeks. Patients underwent clinical examination at weekly intervals. Haematological assessment was made weekly for 7 weeks, and biochemical variables were measured once a week or once every 2 weeks for 6 weeks. Endoscopy was repeated at 6 weeks unless the patient had to be excluded from the trial because of incessant pain after 14 days. No antacid or other treatment was allowed. Seventy-eight per cent of the patients became free of symptoms when treated with cimetidine, and 47% when treated with placebo (chi2 = 5,2235; P less than 0,025 in favour of cimetidine). Endoscopic evidence of healing revealed an improvement of 69,5% in those treated with cimetidine and one of 42% in those treated with placebo (chi2 = 3,8731; P less than 0,05 in favour of cimetidine). No haematological or biochemical changes were noted. It is concluded that the histamine H2-receptor antagonists have a definite place in the treatment of duodenal ulceration.
 ...
PMID:Treatment of duodenal ulcers with cimetidine. 34 63

In a controlled double-blind clinical trial of 39 in-patients with gastric ulcer the effect of cimetidine on ulcer healing, ulcer pain and pentagastrin-stimulated acid and pepsin secretion was measured. A faster healing rate in the cimetidine group was statistically not significant. Cimetidine had no effect on ulcer pain and pentagastrin-stimulated acid and pepsin secretion. There were no serious untoward reactions.
 ...
PMID:[In-patient treatment of peptic ulcer with cimetidine. II. Controlled double-blind trial on gastric ulcer patients (author's transl)]. 34 18

Cimetidine, a new histamine H2-receptor antagonist (H.H2.R.A.) is a potent inhibitor of basal and stimulated gastric acid secretion. Contrary to anticholinergics, it does not affect gastric emptying nor does it decrease lower oesophageal sphincter pressure; cimetidine may therefore be used as the treatment of reflux oesophagitis. After prolonged administration of currently used therapeutic doses, basal and post-prandial serum gastrin levels remain unchanged and the parietal cell mass is not increases. Cimetidine toxicity is very low. Cimetidine is effective in promoting healing and pain relief of gastric and duodenal ulcer. In the latter long-term treatment for prevention of relapse is efficient, but the appraisal of its safety remains debated. Efficiency of H.H2.R.A. in the prophylaxis of gastrointestinal haemorrhage in patients with fulminant hepatic failure has been proven. Furthermore, cimetidine has a dramatic ability to control haemorrhage from acute erosive lesions in any seriously-ill patient. It may also be of benefit in the treatment of bleeding from gastric or duodenal ulcer and, whatewer the lesion, in the prevention of bleeding recurrence. In the Zollinger-Ellison syndrome, good results have been obtained but cimetidine treatment must be decided and supervised only by well-informed specialists. Lastly, in patients with severe exocrine pancreatic insufficiency, cimetidine prevents gastric degradation of orally administered pancreatic extracts and decreases steatorrhea.
 ...
PMID:[Cimetidine. Clinical pharmacology and toxicity (author's transl)]. 35 5

Following 3x200 mg Tagament (cymetidine SK & F) tablets at meals and 2 in the evening (5 per day) for an average of 31 days, complete endoscopic cure was obtained after 29 days (duodenal patients) and 35 days (gastric patients) in 26/27 subjects with slow healing histories (17 with duodenal and 10 with gastric ulcer). Rapid regression of pain and dyspepsia was observed form the outset and there was a marked reduction in the consumption of antacid preparation. Its marked efficacy and good tolerance make Tagamet a drug of choice in the treatment of peptic, duodenal and gastric ulcers.
 ...
PMID:[Preliminary results of treatment with Tagamet (cimetidine SK and F) in gastric and duodenal ulcers]. 35 35

Thirty six patients with active duodenal ulcers were studied in this double blind work. 19 received placebo and 17 Cimetidine: 1 gr./day. The endoscopic control after 21 days, showed healing in 81,2% of the cases treated with Cimetidine and in 22,2% of those with placebo. After 42 days of continous treatment with Cimetidine the healing of duodenal ulcers was 82,3% against 50% with placebo; the difference being highly statestically significant; p less than 0.01. The symptoms improved with Cimetidine revealing less diurnal and nocturnal pain complete disappearance of nausea and vomit and a significant decreased ingestion of alkali tablets.
 ...
PMID:[Cimetidine in the treatment of the active duodenal ulcer]. 36 63


1 2 3 4 Next >>